CLENPIQ
Total Payments
$1.1M
Transactions
22,702
Doctors
5,824
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $121,658 | 279 | 220 |
| 2023 | $135,673 | 652 | 447 |
| 2022 | $92,244 | 1,140 | 715 |
| 2021 | $111,591 | 1,145 | 652 |
| 2020 | $121,766 | 1,589 | 1,131 |
| 2019 | $190,169 | 7,836 | 3,041 |
| 2018 | $278,725 | 10,005 | 3,622 |
| 2017 | $8,232 | 56 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $549,449 | 53 | 51.8% |
| Food and Beverage | $365,060 | 22,491 | 34.4% |
| Consulting Fee | $111,848 | 36 | 10.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,242 | 7 | 1.6% |
| Travel and Lodging | $16,160 | 71 | 1.5% |
| Education | $297.73 | 44 | 0.0% |
Payments by Type
Research
$549,449
53 transactions
General
$510,609
22,649 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years | Ferring International Pharmascience Center US | $359,491 | 0 |
| Clenpiq Low Residue Diet Study | Ferring Pharmaceuticals Inc. | $96,427 | 0 |
| The Effects and Tolerability of a Prescribed Low Residue Diet the Day Before Colonoscopy on the Cleanliness of the Colon vs. the Traditional Clear Liquid, Day Before Diet With the Use of the Clenpiq Bowel Purgative | Ferring Pharmaceuticals Inc. | $49,665 | 0 |
| The Effects and Tolerability of a Prescribed Low Residue Diet the Day Before Colonoscopy on the Cleanliness of the Colon vs. the Traditional Clear Liquid, Day Before Diet with the use of the Clenpiq Bowel Purgative | Ferring Pharmaceuticals Inc. | $40,000 | 1 |
| Randomized Comparison of the Impact of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid versus Polyethylene Glycol Bowel Preparation on Inpatient Colonoscopy Quality Parameters | Ferring Pharmaceuticals Inc. | $3,866 | 0 |
Top Doctors Receiving Payments for CLENPIQ — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Gastroenterology | Charlotte, NC | $845.72 | 63 |
| , MD | Gastroenterology | New York, NY | $802.24 | 67 |
| James Sherman | — | Los Angeles, CA | $795.96 | 54 |
| , MD | Gastroenterology | Beverly Hills, CA | $781.45 | 54 |
| , M.D | Gastroenterology | New York, NY | $778.43 | 42 |
| , MD | Internal Medicine | New York, NY | $739.56 | 44 |
| , M.D | Colon & Rectal Surgery | West Hollywood, CA | $694.18 | 36 |
| , M.D | Specialist | Fort Lauderdale, FL | $684.21 | 43 |
| , M.D | Gastroenterology | Houston, TX | $682.88 | 36 |
| , M.D | Gastroenterology | New York, NY | $666.69 | 44 |
| , M.D | Internal Medicine | Beverly Hills, CA | $630.39 | 34 |
| , M.D | Specialist | Torrance, CA | $612.12 | 37 |
| , MD | Gastroenterology | New York, NY | $609.23 | 52 |
| , M.D | Gastroenterology | New York, NY | $608.50 | 32 |
| , MD | Gastroenterology | Henderson, NV | $571.08 | 45 |
| , MD | Gastroenterology | Mount Vernon, OH | $561.12 | 45 |
| , M.D., MSC | Gastroenterology | Smithtown, NY | $518.59 | 27 |
| , MD | Gastroenterology | New York, NY | $517.51 | 37 |
| , MD | Gastroenterology | New York, NY | $508.87 | 27 |
| , M.D | Gastroenterology | New York, NY | $507.35 | 35 |
| , MD | Gastroenterology | White Plains, NY | $505.76 | 49 |
| , MD | Gastroenterology | New York, NY | $500.10 | 39 |
| , M.D | Gastroenterology | Bethesda, MD | $495.59 | 37 |
| , M.D | Gastroenterology | North Miami, FL | $482.98 | 33 |
| , M.D | Gastroenterology | New York, NY | $481.75 | 39 |
Ad
Manufacturing Companies
- Ferring Pharmaceuticals Inc. $700,567
- Ferring International Pharmascience Center US $359,491
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 5,824
- Transactions 22,702
About CLENPIQ
CLENPIQ is a drug associated with $1.1M in payments to 5,824 healthcare providers, recorded across 22,702 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals Inc..
Payment data is available from 2017 to 2024. In 2024, $121,658 was paid across 279 transactions to 220 doctors.
The most common payment nature for CLENPIQ is "Unspecified" ($549,449, 51.8% of total).
CLENPIQ is associated with 5 research studies, including "A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years" ($359,491).